Download PDF
Pharmacopsychiatry 2022; 55(01): 16-23
DOI: 10.1055/a-1551-3756
Review

Candidate Psychotropics against SARS – CoV – 2: A Narrative Review

Mohsen Khosravi 
Department of Psychiatry and Clinical Psychology, Zahedan University of Medical Sciences, Zahedan, Iran
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Since few therapeutic options are clinically accessible for coronavirus disease 2019 (COVID-19), effective, safe, and globally available pharmaceuticals need to be urgently developed to prevent severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) and alleviate the severity of COVID-19. In this regard, the present paper is intended to provide an extensive review of the clinical and preclinical evidence on the psychotropics’ anti-SARS-CoV-2 effects, giving an insight into their potential applications for patients with a proven or high likelihood of COVID-19 pneumonia. The results showed that psychotropic drugs such as melatonin, lithium carbonate, valproate, olanzapine, quetiapine, clozapine, fluoxetine, escitalopram, fluvoxamine, and cannabidiol could help lower the mortality due to SARS-CoV-2 infection. According to these medications’ direct immunomodulatory actions against the destructive cytokine storm, as well as other direct/indirect mechanisms (e. g., the endolysosomal pathway modulation, interactions with specific receptors, and membrane fusion), it was perceived that such drugs could effectively weaken the worsened immune response and avoid adult respiratory distress syndrome and acute lung injury. According to the author’s analysis of the currently available evidence, there is significant support for psychotropics as complementary interventions during SARS-CoV-2 infection. However, further studies need to be carried out to assess the effects of the above psychotropic drugs in vitro and clinical settings.

Key words

psychotropic - review - SARS-CoV-2


Publication History

Received: 18 May 2021
Received: 04 July 2021

Accepted: 09 July 2021

Article published online:
16 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Wiersinga WJ, Rhodes A, Cheng AC. et al Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. J Am Med Assoc 2020; 324: 782-793
    CrossrefPubMedGoogle Scholar
  • 2 Rizk JG, Kalantar-Zadeh K, Mehra MR. et al Pharmaco-immunomodulatory therapy in COVID-19. Drugs 2020; 80: 1267-1292
    CrossrefPubMedGoogle Scholar
  • 3 Alijotas-Reig J, Esteve-Valverde E, Belizna C. et al Immunomodulatory therapy for the management of severe COVID-19. Beyond the antiviral therapy: a comprehensive review. Autoimmun Rev 2020; 19: 102569
    CrossrefPubMedGoogle Scholar
  • 4 Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38: 1-9
    PubMedGoogle Scholar
  • 5 Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020; 130: 2202-2205
    CrossrefPubMedGoogle Scholar
  • 6 Lu L, Zhang H, Zhan M. et al Preventing mortality in COVID-19 patients: which cytokine to target in a raging storm?. Front Cell Dev Biol 2020; 8: 677
    CrossrefPubMedGoogle Scholar
  • 7 Toubasi AA, AbuAnzeh RB, Tawileh HB. et al A meta-analysis: the mortality and severity of COVID-19 among patients with mental disorders. Psychiatry Res 2021; 299: 113856
    CrossrefPubMedGoogle Scholar
  • 8 Villoutreix BO, Beaune PH, Tamouza R. et al Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders. Drug Discov Today 2020; 25: 1287-1290
    CrossrefPubMedGoogle Scholar
  • 9 MacLure M. ‘Clarity Bordering on Stupidity’: Where’s the Quality in Systematic Review?. 1st ed. London: Routledge; 2007
    Google Scholar
  • 10 Reiter RJ, Abreu-Gonzalez P, Marik PE. et al Therapeutic algorithm for use of melatonin in patients with COVID-19. Front Med 2020; 7: 226
    CrossrefPubMedGoogle Scholar
  • 11 Anderson G, Reiter RJ. Melatonin: roles in influenza, Covid-19, and other viral infections. Rev Med Virol 2020; 30: e2109
    CrossrefPubMedGoogle Scholar
  • 12 Sehirli AO, Sayiner S, Serakinci N. Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147). Mol Biol Rep 2020; 47: 8229-8233
    CrossrefPubMedGoogle Scholar
  • 13 Juybari KB, Pourhanifeh MH, Hosseinzadeh A. et al Melatonin potentials against viral infections including COVID-19: current evidence and new findings. Virus Res 2020; 287: 198108
    CrossrefPubMedGoogle Scholar
  • 14 Castillo RR, Quizon GR, Juco MJ. et al Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series. Melatonin Research 2020; 3: 297-310
    CrossrefPubMedGoogle Scholar
  • 15 Tan DX, Hardeland R. Targeting host defense system and rescuing compromised mitochondria to increase tolerance against pathogens by melatonin may impact outcome of deadly virus infection pertinent to COVID-19. Molecules 2020; 25: 4410
    CrossrefPubMedGoogle Scholar
  • 16 Chen G, Wu DI, Guo W. et al Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130: 2620-2629
    CrossrefPubMedGoogle Scholar
  • 17 Reiter RJ, Sharma R, Ma Q, Dominquez-Rodriguez A. et al Melatonin inhibits COVID-19-induced cytokine storm by reversing aerobic glycolysis in immune cells: a mechanistic analysis. Med Drug Discov 2020; 6: 100044
    CrossrefPubMedGoogle Scholar
  • 18 Loh D. The potential of melatonin in the prevention and attenuation of oxidative hemolysis and myocardial injury from cd147 SARS-CoV-2 spike protein receptor binding. Melatonin Research 2020; 3: 380-416
    CrossrefPubMedGoogle Scholar
  • 19 Artigas L, Coma M, Matos-Filipe P. et al In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS One 2020; 15: e0240149
    CrossrefPubMedGoogle Scholar
  • 20 Feitosa EL, Júnior FT, Neto JA. et al COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor. Int J Med Sci 2020; 17: 2133-2146
    CrossrefPubMedGoogle Scholar
  • 21 Grifoni A, Weiskopf D, Ramirez SI. et al Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020; 181: 1489-1501.e15
    CrossrefPubMedGoogle Scholar
  • 22 Maestroni G. Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccines. J Neuroimmune Pharmacol 2020; 15: 572-573
    CrossrefPubMedGoogle Scholar
  • 23 Rajkumar RP. Lithium as a candidate treatment for COVID-19: Promises and pitfalls. Drug Dev Res 2020; 81: 782-785
    CrossrefPubMedGoogle Scholar
  • 24 Spuch C, López-García M, Rivera-Baltanás T. et al Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol 2020; 11: 557629
    CrossrefPubMedGoogle Scholar
  • 25 Murru A, Manchia M, Hajek T. et al Lithium’s antiviral effects: a potential drug for CoViD-19 disease?. Int J Bipolar Disord 2020; 8: 21
    CrossrefPubMedGoogle Scholar
  • 26 Ishii N, Terao T, Hirakawa H. Association between trace levels of lithium in drinking water and COVID-19–associated mortality. Bipolar Disord 2021; 23: 100
    CrossrefPubMedGoogle Scholar
  • 27 Unal G, Turan B, Balcioglu YH. Immunopharmacological management of COVID-19: potential therapeutic role of valproic acid. Med Hypotheses 2020; 143: 109891
    CrossrefPubMedGoogle Scholar
  • 28 Wu SY, Tang SE, Ko FC. et al Valproic acid attenuates acute lung injury induced by ischemia-reperfusion in rats. Anesthesiology 2015; 122: 1327-1337
    CrossrefPubMedGoogle Scholar
  • 29 Royce SG, Dang W, Ververis K. et al Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease. Epigenetics 2011; 6: 1463-1470
    CrossrefPubMedGoogle Scholar
  • 30 Ichiyama T, Okada K, Lipton JM. et al Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κB. Brain Res 2000; 857: 246-251
    CrossrefPubMedGoogle Scholar
  • 31 Pitt B, Sutton NR, Wang Z. et al Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol 2021; 898: 173988
    CrossrefPubMedGoogle Scholar
  • 32 Bhargava P, Panda P, Ostwal V. et al Repurposing valproate to prevent acute respiratory distress syndrome/acute lung injury in COVID-19: a review of immunomodulatory action. Cancer Res Stat Treat 2020; 3: 65
    CrossrefPubMedGoogle Scholar
  • 33 Gordon DE, Jang GM, Bouhaddou M. et al A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020; 583: 459-468
    CrossrefPubMedGoogle Scholar
  • 34 Hoertel N, Sánchez-Rico M, Vernet R. et al Observational study of haloperidol in hospitalized patients with COVID-19. PLoS One 2021; 16: e0247122
    CrossrefPubMedGoogle Scholar
  • 35 Triggiani M, Gentile M, Secondo A. et al Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 2001; 166: 4083-4091
    CrossrefPubMedGoogle Scholar
  • 36 Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 2000; 68: 29-39
    CrossrefPubMedGoogle Scholar
  • 37 Altschuler EL, Kast RE. Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses 2005; 65: 65-67
    CrossrefPubMedGoogle Scholar
  • 38 Altschuler EL, Kast RE. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS). Med Hypotheses 2020; 141: 109774
    CrossrefPubMedGoogle Scholar
  • 39 Hawkins M, Sockalingam S, Bonato S. et al A rapid review of the pathoetiology, presentation, and management of delirium in adults with COVID-19. J Psychosom Res 2021; 141: 110350
    CrossrefPubMedGoogle Scholar
  • 40 Khosravi M. Quetiapine versus clozapine in treating psychiatric patients with Severe COVID-19: a netosis-based opinion. Electron J Gen Med 2021; 18: em301
    CrossrefPubMedGoogle Scholar
  • 41 Khosravi M. COVID-19 Pandemic: what are the risks and challenges for schizophrenia?. Clin Schizophr Relat Psychoses 2020; 14: 110320
    PubMedGoogle Scholar
  • 42 Hamed MG, Hagag RS. The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients. Med Hypotheses 2020; 144: 110140
    CrossrefPubMedGoogle Scholar
  • 43 Hoertel N, Sánchez-Rico M, Vernet R. et al Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry 2021
    PubMed
  • 44 Schloer S, Brunotte L, Goretzko J. et al Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect 2020; 9: 2245-2255
    CrossrefPubMedGoogle Scholar
  • 45 Hoffmann M, Kleine-Weber H, Schroeder S. et al SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280.e8
    CrossrefPubMedGoogle Scholar
  • 46 Zimniak M, Kirschner L, Hilpert H. et al The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2. Sci Rep 2021; 11: 5890
    CrossrefPubMedGoogle Scholar
  • 47 Lenze EJ, Mattar C, Zorumski CF. et al Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020; 324: 2292-2300
    CrossrefPubMedGoogle Scholar
  • 48 Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents 2020; 56: 106044
    CrossrefPubMedGoogle Scholar
  • 49 Fung TS, Liu DX. The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy induction in cells infected with coronavirus infectious bronchitis virus. Virology 2019; 533: 34-44
    CrossrefPubMedGoogle Scholar
  • 50 Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation. Am J Cardiovasc Drugs 2003; 3: 149-162
    CrossrefPubMedGoogle Scholar
  • 51 Anil SM, Shalev N, Vinayaka AC. et al Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and proinflammatory activity in macrophages. Sci Rep 2021; 11: 1462
    CrossrefPubMedGoogle Scholar
  • 52 Wang B, Kovalchuk A, Li D. et al In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging 2020; 12: 22425-22444
    PubMedGoogle Scholar
  • 53 Nagoor Meeran MF, Sharma C, Goyal SN. et al CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections. Drug Dev Res 2021; 82: 7-11
    CrossrefPubMedGoogle Scholar
  • 54 O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010; 215: 611-616
    CrossrefPubMedGoogle Scholar
  • 55 Huang S, Goplen NP, Zhu B. et al Macrophage PPAR-γ suppresses long-term lung fibrotic sequelae following acute influenza infection. PLoS One 2019; 14: e0223430
    CrossrefPubMedGoogle Scholar
  • 56 Lowe HI, Toyang NJ, McLaughlin W. Potential of cannabidiol for the treatment of viral hepatitis. Pharmacognosy Res 2017; 9: 116-118
    CrossrefPubMedGoogle Scholar
  • 57 Milam JE, Keshamouni VG, Phan SH. et al PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L891-L901
    CrossrefPubMedGoogle Scholar
  • 58 Esposito G, Pesce M, Seguella L. et al The potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol 2020; 177: 4967-4970
    CrossrefPubMedGoogle Scholar
  • 59 Larsen C, Shahinas J. Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res 2020; 12: 129-141
    CrossrefPubMedGoogle Scholar
  • 60 DeRoo SS, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA 2020; 323: 2458-2459
    CrossrefPubMedGoogle Scholar
  • 61 Khosravi M. Ursodeoxycholic Acid in Patients with Treatment-Resistant Schizophrenia Suffering From Coronavirus Disease 2019: A Hypothesis Letter. Front Psychiatry 2021; 12: 657316
    CrossrefPubMedGoogle Scholar